Recombinant Human Polyclonal Antibodies to Treat Disease

Published on:
April 26, 2021
Written by:
Steven Chamow, Bryan Monroe, Chuck Olson

Congratulations to Alira Health’s Steven Chamow, PhD, Senior Vice President, CMC and founder of Chamow & Associates, and to Bryan Monroe and Chuck Olson, Senior Consultants, on their contributions to “Generation of recombinant hyperimmune globulins from diverse B-cell repertoires” published in the current issue of Nature Biotechnology.

The publication by Sheila Keating, Rena Mizrahi and colleagues is a result of a large collaborative effort organized and coordinated by GigaGen, Inc., a US biotechnology company specializing in the discovery and development of recombinant biotherapeutic medicines. It describes a microfluidics and molecular genomics strategy for capturing diverse mammalian antibody repertoires to create recombinant multivalent antibodies.

This novel method generates mixtures of thousands of recombinant antibodies; mixtures that are enriched for antibodies with specificity and activity against predefined therapeutic targets. The antibodies are derived from convalescent or vaccinated human donors or from immunized mice.

Because the method produces cell lines in which multiple copies of the expression construct are present in the genome, insertion cannot be random. Steve’s team guided the use of CHO cell lines engineered with a Flp recombinase recognition target landing pad to achieve stable expression of recombinant heavy and light chains in polyclonal cell banks.

GigaGen reports that it has generated potent hyperimmune recombinant polyclonal antibody therapies against SARS-CoV-2, Zika virus and human thymocytes, the latter to treat graft-versus-host disease.

Click here to access the full publication.

For more information, contact Steven Chamow.

Related news

Research & Development
Events October 5, 2021
Event: STEM Week – Life Sciences Jobs: Demystifying Career Paths 101
Join the MetroWest STEM Education Network is delighted to host a special panel discussion for Massachusetts STEM Week 2021.
Due Diligence Research & Development
Publications August 18, 2021
Infographic: Indication Prioritization and Pre-Commercial Value Assessment
Download our infographic on Indication Prioritization and Pre-Commercial Value Assessment.
Pharma Research & Development
Publications August 2, 2021
Infographic: Prioritization Strategy of R&D Targets for Biotech Company
Download our infographic on Prioritization Strategy of R&D Targets for Biotech Company
Research & Development
Publications June 9, 2021
EU Supply Integrity Guidelines
Check out Alira Health's latest publication, “EU Supply Integrity Guidelines”. In the document, best practices for European distribution and supply integrity management are highlighted(...)
Research & Development
Publications May 27, 2021
Buffers – Navigating New Demands On Downstream Raw Materials
The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing(...)
Research & Development
News March 15, 2021
Alira Health Welcomes Nikole Siegmund, Vice President, Preclinical
BOSTON, USA – Alira Health (, a leading international healthcare and life sciences advisory firm, is pleased to announce that Nikole Siegmund has joined the firm(...)
Research & Development
Publications March 9, 2021
A Primer on Potency Assays for Release of Biologics
A key criterion in determining the quality of a biologic product is whether it has maintained its biological activity or “potency.”

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.